StockSignal
  • Screen for fundamentally interesting stocks
Sign in
Lepu Medical Technology Co., Ltd. logo

Lepu Medical Technology Co., Ltd.

300003 · XSHE · Medical Devices · China

Fcf Positive 3yProfitable 3y
Market Capitalization33.49B CNY
Trailing P/E79.00 CNY
52-Week Change34.95 CNY
Forward Annual Dividend Yield3.58%
Beta0.3150 CNY

Lepu Medical Technology Co., Ltd. is a prominent company in the healthcare sector, specializing in the research, development, manufacture, and sale of high-quality medical devices and pharmaceuticals. The company's primary focus is on cardiovascular products, which include interventional devices, cardiac rhythm management products, and surgical products, providing crucial solutions for heart-related health issues. Furthermore, Lepu Medical augments its offerings with in vitro diagnostics and general medical supplies. Lepu Medical's innovative approach and commitment to advancing medical technology have enabled it to secure a significant role within both the domestic Chinese healthcare market and international markets. The company is dedicated to enhancing the quality of life through its product offerings and has established itself as a key player in supporting modern healthcare practices. With its broad portfolio, Lepu Medical serves a diverse customer base that includes hospitals, healthcare professionals, and medical institutions. The company's robust growth and global expansion efforts highlight its influence and importance in the ever-evolving medical technology landscape.

Industry

Medical Devices

Healthcare sector · China

Stories

Structural patterns identified in Lepu Medical Technology Co., Ltd.

Screen for these patterns
Story type: Situational

Retained Earnings

Three equity signals have aligned: retained earnings are a substantial portion of equity, the equity ratio is healthy, and dividend payouts are moderate. Together these describe an equity base built through profit accumulation over multiple reporting periods.

retained earnings weightequity ratiodividend payout intensity

Key Metrics

Market Capitalization
33.49BCNY
NormalMar 18, 2026
Trailing P/E
79.00CNY
AboveNormalMar 18, 2026
Revenue (TTM)
6.26BCNY
NormalMar 18, 2026
Profit Margin
6.81%
NormalMar 18, 2026
Beta
0.3150CNY
NormalMar 18, 2026
52-Week Change
34.95CNY
ExtremeMar 18, 2026
Forward Annual Dividend Yield
3.58%
NormalMar 18, 2026
Forward Yield
3.58%
Above 5Y avg (1.92%)
Annual Rate
CNY 0.65
Paid annual
Payout Ratio
128.1%
High
Loading dividend history...

Track Record

Frequency
Annual
Payback Period
99.8 yr
Years to recoup investment via dividends alone

Upcoming

Ex-Dividend Date
Sep 23, 2025

Screen for dividend patterns

Find other stocks with similar dividend characteristics in the screener.

Dividend Fortress
→
dividend consistency
dividend quality
free cash flow conversion
Open in Screener
Dividend Growth Track
→
dividend growth rate
dividend streak
dividend consistency
Open in Screener
Dividend Sustainability
→
dividend quality
common dividends to free cash flow
dividend stress
Open in Screener
Valuation9
Market Capitalization
33.49BCNY
NormalMar 18, 2026
Enterprise Value
36.47BCNY
NormalMar 18, 2026
Trailing P/E
79.00CNY
AboveNormalMar 18, 2026
Forward P/E
25.24CNY
NormalMar 18, 2026
PEG Ratio
25.24CNY
ExtremeMar 18, 2026
Price to Sales (TTM)
5.35CNY
NormalMar 18, 2026
Price to Book (MRQ)
2.09CNY
NormalMar 18, 2026
Enterprise to Revenue
5.83CNY
NormalMar 18, 2026
Enterprise to EBITDA
28.05CNY
NormalMar 18, 2026
Profitability & Growth60
Gross Margin
64.51%
NormalMar 18, 2026
Profit Margin
6.81%
NormalMar 18, 2026
Operating Margin
29.35%
NormalMar 18, 2026
Return on Assets (TTM)
0.0188CNY
NormalMar 18, 2026
Return on Equity (TTM)
0.0234CNY
NormalMar 18, 2026
Revenue (TTM)
6.26BCNY
NormalMar 18, 2026
Revenue per Share (TTM)
3.39CNY
NormalMar 18, 2026
Quarterly Revenue Growth
0.1200CNY
NormalMar 18, 2026
Gross Profit (TTM)
3.71BCNY
NormalMar 18, 2026
EBITDA
1.30BCNY
ExtremeMar 18, 2026
Net Income (TTM)
426.33MCNY
NormalMar 18, 2026
Quarterly Earnings Growth (YoY)
1.76CNY
AboveNormalMar 18, 2026
Operating Cash Flow (TTM)
1.32BCNY
NormalMar 18, 2026
Levered Free Cash Flow (TTM)
42.03MCNY
NormalMar 18, 2026
Forward Annual Dividend Rate
0.6510CNY
NormalMar 18, 2026
Forward Annual Dividend Yield
3.58%
NormalMar 18, 2026
Trailing Annual Dividend Rate
0.1628CNY
NormalMar 18, 2026
Trailing Annual Dividend Yield
0.90%
NormalMar 18, 2026
5-Year Average Dividend Yield
192.00%
ExtremeMar 18, 2026
Payout Ratio
1.28CNY
AboveNormalMar 18, 2026
Minority Interest (Equity)
1.54B
NormalFY2024 · Dec 31, 2024
Revenue
6.10B
NormalFY2024 · Dec 31, 2024
Cost of Goods Sold
2.39B
NormalFY2024 · Dec 31, 2024
Gross Profit
3.72B
NormalFY2024 · Dec 31, 2024
Operating Income
716.96M
NormalFY2024 · Dec 31, 2024
Pre-tax Income
225.76M
NormalFY2024 · Dec 31, 2024
Income Tax Expense
28.47M
NormalFY2024 · Dec 31, 2024
Net Income
197.29M
NormalFY2024 · Dec 31, 2024
EBIT
406.76M
NormalFY2024 · Dec 31, 2024
ebitda-income
1.30B
NormalFY2024 · Dec 31, 2024
Research & Development
769.56M
NormalFY2024 · Dec 31, 2024
Selling, General & Administrative
958.45M
NormalFY2024 · Dec 31, 2024
Other Operating Expenses
86.39M
NormalFY2024 · Dec 31, 2024
Non-operating Interest Income
115.51M
NormalFY2024 · Dec 31, 2024
Non-operating Interest Expense
181.00M
NormalFY2024 · Dec 31, 2024
EPS (Basic)
0.1336
NormalFY2024 · Dec 31, 2024
EPS (Diluted)
0.1336
NormalFY2024 · Dec 31, 2024
Basic Shares Outstanding
1.85BShares
NormalFY2024 · Dec 31, 2024
Diluted Shares Outstanding
1.85BShares
NormalFY2024 · Dec 31, 2024
Net Income from Continuing Operations
197.29M
NormalFY2024 · Dec 31, 2024
Minority Interests (P&L)
49.64M
NormalFY2024 · Dec 31, 2024
Preferred Stock Dividends
0.00
NormalFY2024 · Dec 31, 2024
Operating Cash Flow
432.94M
NormalFY2024 · Dec 31, 2024
Free Cash Flow
75.82M
NormalFY2024 · Dec 31, 2024
Cash & Cash Equivalents (End of Period)
3.61B
NormalFY2024 · Dec 31, 2024
Net Income (CF Statement)
197.29M
NormalFY2024 · Dec 31, 2024
Other Non-cash Items
263.05M
NormalFY2024 · Dec 31, 2024
Change in Accounts Receivable (CF)
-62.84M
NormalFY2024 · Dec 31, 2024
Change in Other Assets/Liabilities
35.44M
NormalFY2024 · Dec 31, 2024
Capital Expenditures
-628.79M
NormalFY2024 · Dec 31, 2024
Net Acquisitions
-15.76M
NormalFY2024 · Dec 31, 2024
Purchase of Investments
-803.96M
NormalFY2024 · Dec 31, 2024
Sale of Investments
646.13M
NormalFY2024 · Dec 31, 2024
Other Investing Activity
58.48M
NormalFY2024 · Dec 31, 2024
Net Investing Cash Flow
-743.90M
NormalFY2024 · Dec 31, 2024
Long-term Debt Issuance
3.17B
NormalFY2024 · Dec 31, 2024
Long-term Debt Payments
-2.29B
NormalFY2024 · Dec 31, 2024
Common Dividends Paid
-990.89M
NormalFY2024 · Dec 31, 2024
Other Financing Charges
-313.28M
NormalFY2024 · Dec 31, 2024
Net Financing Cash Flow
-430.00M
NormalFY2024 · Dec 31, 2024
Financial Strength30
Shares Outstanding
1.88BShares
NormalMar 18, 2026
Float Shares
1.12BCNY
NormalMar 18, 2026
% Held by Insiders
0.3860CNY
NormalMar 18, 2026
% Held by Institutions
0.1006CNY
NormalMar 18, 2026
Total Cash (MRQ)
3.94BCNY
NormalMar 18, 2026
Total Cash per Share (MRQ)
2.14CNY
NormalMar 18, 2026
Total Debt (MRQ)
5.83BCNY
NormalMar 18, 2026
Total Debt to Equity (MRQ)
32.83CNY
ExtremeMar 18, 2026
Current Ratio (MRQ)
1.89CNY
NormalMar 18, 2026
Book Value per Share (MRQ)
8.70CNY
NormalMar 18, 2026
Total Assets
24.57B
NormalFY2024 · Dec 31, 2024
Total Current Assets
8.44B
NormalFY2024 · Dec 31, 2024
Total Liabilities
7.83B
NormalFY2024 · Dec 31, 2024
Total Non-current Assets
16.14B
NormalFY2024 · Dec 31, 2024
Total Non-current Liabilities
4.22B
NormalFY2024 · Dec 31, 2024
Total Current Liabilities
3.61B
NormalFY2024 · Dec 31, 2024
Cash
3.63B
NormalFY2024 · Dec 31, 2024
Cash Equivalents
85.55M
NormalFY2024 · Dec 31, 2024
Cash & Cash Equivalents
3.72B
NormalFY2024 · Dec 31, 2024
Other Short-term Investments
274.86M
NormalFY2024 · Dec 31, 2024
Accounts Receivable
1.53B
NormalFY2024 · Dec 31, 2024
Inventory
2.03B
NormalFY2024 · Dec 31, 2024
Accounts Payable
797.15M
NormalFY2024 · Dec 31, 2024
Short-term Debt
1.89B
NormalFY2024 · Dec 31, 2024
Other Current Liabilities
60.74M
NormalFY2024 · Dec 31, 2024
Long-term Debt
3.88B
NormalFY2024 · Dec 31, 2024
Common Stock (Book)
1.88B
NormalFY2024 · Dec 31, 2024
Retained Earnings
9.43B
NormalFY2024 · Dec 31, 2024
Total Shareholders' Equity
16.74B
NormalFY2024 · Dec 31, 2024
Treasury Stock
608.49M
ExtremeFY2024 · Dec 31, 2024
Market & Technical9
52-Week Low
10.11CNY
NormalMar 18, 2026
52-Week High
21.60CNY
NormalMar 18, 2026
52-Week Change
34.95CNY
ExtremeMar 18, 2026
Beta
0.3150CNY
NormalMar 18, 2026
50-Day MA
18.22CNY
NormalMar 18, 2026
200-Day MA
16.95CNY
NormalMar 18, 2026
Avg 10-Day Volume
38.07MCNY
NormalMar 18, 2026
Avg 30-Day Volume
32.90MCNY
NormalMar 18, 2026
Diluted EPS (TTM)
0.2300CNY
NormalMar 18, 2026

Coordination

Placeholder CorpCoordination
Example HoldingsCoordination
Sample IncCoordination

Supply Chain

Medical Devices Supply Chain

The medical devices supply chain is shaped by three structural constraints that most manufacturing industries do not face: a regulatory classification cascade where risk level determines the years of validation required before a product can be sold, sterilization and biocompatibility requirements that restrict which materials and processes are permitted, and installed base dependency where hospitals commit to ecosystems that cannot be switched without replacing training, consumables, and data infrastructure.

StockSignal
  • Blog
  • Industries
  • Glossary
  • Stories
  • Coordinations
  • Constraint Archetypes
  • Legal

Contact

© 2026 StockSignal. All rights reserved.